Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NORDTREAT: Biomarker-Stratified Top-Down Treatment in IBD
NCT05180175Phase 4Completed
- Sponsor
- Region Örebro län
- Start
- Feb 2022
- Primary completion
- Jan 2025
- Countries
- 4
01
Overview
Phase 4, randomised, open-label trial in inflammatory bowel disease (IBD), ulcerative colitis (UC) and Crohn's disease (2 arms), sponsored by Region Örebro län. Primary endpoint: Composite of corticosteroid-free clinical remission and endoscopic remission at Week 52. Started Feb 2022; status: completed.
02
Conditions
inflammatory bowel disease (IBD)ulcerative colitis (UC)Crohn's disease
Beyond the preview
Go deeper on NCT05180175.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05180175.